Treatments initially developed for T2DM including glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and sodium-glucose transporter 2 (SGLT2) inhibitors now have proven benefits for obesity-related cardiometabolic diseases beyond glucose lowering. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.